Results 21 to 30 of about 5,275 (178)
PLoS ONE, 2019 Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD).
Hee Jung Jeon, Jieun Oh, Dong Ho Shin
doaj +1 more source
Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout
Научно-практическая ревматология, 2019 During the first months after initiation of urate-lowering therapy in patients with gout, the risk of exacerbating arthritis substantially increases, frequently causing them to refuse this treatment.
M. N. Chikina
doaj +1 more source
The impact of urate-lowering therapy on kidney function (IMPULsKF)
Počki, 2017 The concept of trial launched in Ukraine in 2017 with POEM design and 36-months duration is presented. It aims to investigate the impact of two target levels of urate-lowering therapy caused by hyperuricemia on kidney function and chronic kidney disease (
D.D. Ivanov
doaj +1 more source
Arthritis Research & Therapy, 2022 Background Uncontrolled/refractory gout patients are recalcitrant/intolerant to oral urate-lowering therapies (ULTs), experiencing frequent gout flares, functionally limiting tophi, and low quality of life.
John K. Botson +5 more
doaj +1 more source
Personalized Medicine of Urate-Lowering Therapy for Gout
, 2020 Gout is a common and complex form of arthritis that is characterised with hyperuricaemia. It is required urate-lowering therapy (ULT) for lifelong management. ULT includes decreasing uric acid product in serum, increasing renal urate excretion and promoting uric acid to allantoin for excretion.
Zhang, Y, Yan, D
openaire +4 more sources
Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis? [PDF]
Exploration of Musculoskeletal DiseasesCo-prescription of anti-inflammatory prophylaxis with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids when initiating urate-lowering therapy (ULT) for gout is recommended in clinical guidelines to prevent ULT-induced flares
Edward Roddy +2 more
doaj +1 more source
Comparison Between Early-Onset and Common Gout: A Systematic Literature Review
Rheumatology and Therapy, 2023 Introduction Gout is an inflammatory, metabolic disease associated with a high comorbidity burden including cardiovascular disease, hypertension, type 2 diabetes, hyperlipidemia, renal disease, and metabolic syndrome.
Anthony J. Amatucci +3 more
doaj +1 more source
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease [PDF]
The Permanente Journal, 2018 Hyperuricemia is an independent risk factor for progression of kidney disease.To determine whether lowering serum uric acid level (sUA) to below 6 mg/dL (target) improves mild to moderate chronic kidney disease (CKD) and whether CKD stage influences the benefit of lowering sUA to target.Retrospective epidemiologic cohort study conducted over 8 years ...
Gerald, Levy +3 more
openaire +2 more sources
Factors associated with initiation and persistence of urate-lowering therapy [PDF]
Arthritis Research & Therapy, 2017 Gout is the most common inflammatory arthritic disease and is caused by crystal deposition secondary to persistent hyperuricemia. Etiological treatment with urate-lowering therapy (ULT) has been available since the 1950s but previous studies have demonstrated suboptimal degree of treatment.
Mats Dehlin +5 more
openaire +2 more sources
Adherence with urate-lowering therapies for the treatment of gout [PDF]
Arthritis Research & Therapy, 2009 Abstract Introduction Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout.
Harrold, Leslie R +6 more
openaire +3 more sources